MDM2 and hematologic disorder: Conversely, in hematological malignancies, where p53 mutations are less recurrent, its activity may be likewise compromised by the alterations of MDM2 (Table 1) and ARF (Richmond et al., 2015; Kojima et al., 2016), two regulators of p53.